52.23
-0.895(-1.68%)
Currency In USD
| Previous Close | 53.12 |
| Open | 51.99 |
| Day High | 53.04 |
| Day Low | 51.47 |
| 52-Week High | 111.29 |
| 52-Week Low | 47.25 |
| Volume | 141,310 |
| Average Volume | 1.55M |
| Market Cap | 3.57B |
| PE | 21.67 |
| EPS | 2.41 |
| Moving Average 50 Days | 53.94 |
| Moving Average 200 Days | 75.61 |
| Change | -0.9 |
If you invested $1000 in Lantheus Holdings, Inc. (LNTH) 10 years ago, it would be worth $17,293.05 as of November 14, 2025 at a share price of $52.225. Whereas If you bought $1000 worth of Lantheus Holdings, Inc. (LNTH) shares 5 years ago, it would be worth $4,277.23 as of November 14, 2025 at a share price of $52.225.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lantheus Announces Leadership Transition Plan
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Brian Markison to Retire as Chief Executive Officer; Board Conducting Search for Next CEO Continued Execution of Company’s Strategy to be Led by Prior CEO Mary Anne Heino as Executive Chairperson BEDFORD, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) --
Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
PDUFA Date Set for March 29, 2026BEDFORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disea
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
GlobeNewswire Inc.
Oct 28, 2025 12:30 PM GMT
PDUFA Date Set for August 13, 2026BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow dise